The debate over which form of stem cells will be most beneficial for clinical applications is far from over, and there may well never be a clear “winner.” The true winners will be the patients who will benefit from whichever method proves most feasible, cost effective, broadly accessible, and acceptable to regulatory agencies—whatever cell-based therapies can deliver the cures needed regardless of the source of the cells.
Recent Posts
- ‘Serial Killing’ Cell Therapy From Autolus Lands FDA Approval in Blood Cancer
- World-first stem-cell treatment restores vision in people
- Human stem cell-derived heart cells are safe in monkeys, could treat congenital heart disease
- Markers in iPSC quality control—a new approach to enhance standardization
- Nasal Spray Made From Stem Cells Could Treat Alzheimer’s Disease
- New Stem Cell Data From Space